Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water
- PMID: 9865236
- DOI: 10.3109/15563659809162616
Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water
Erratum in
- J Toxicol Clin Toxicol 1999;37(4):525
Abstract
Introduction: Chronic arsenic toxicity producing various clinical manifestations is currently epidemic in West Bengal, India, Bangladesh, and other regions of the world. Animal studies have indicated that 2,3-dimercaptosuccinic acid can be used as an oral chelating agent. A prospective, double-blind, randomized controlled trial was carried out to evaluate the efficacy and safety of 2,3-dimercaptosuccinic acid for chronic arsenicosis due to drinking arsenic-contaminated (> or = 50 micrograms/L) subsoil water in West Bengal.
Method: Twenty-one consecutive patients with chronic arsenicosis were individually randomized (random number; assignment made by individual not evaluating patients) into 2 groups: 11 patients (10 male, age 25.5 +/- 8 years) received 2,3-dimercaptosuccinic acid 1400 mg/d (1000 mg/m2) in the first week and 1050 mg/d (750 mg/m2) during the next 2 weeks with a repeat course 3 weeks later. The other 10 patients (all male, age 32.2 +/- 9.7 years) were given placebo capsules for the same schedule. The clinical features were evaluated by an objective scoring system before and after treatment. Routine investigations including liver function tests, arsenic concentrations in urine, hair, and nails, and skin biopsy evaluations were also completed.
Results: Though there was improvement in the clinical score of 2,3-dimercaptosuccinic acid-treated patients, similar improvement was observed in the placebo-treated group. There were no statistical differences in the clinical scores between the 2 groups at the beginning and at the end of treatment. Similarly, no differences were found for the other investigated parameters.
Conclusion: Under the conditions of this study, 2,3-dimercaptosuccinic acid was not effective in producing any clinical or biochemical benefit or any histopathological improvement of skin lesions in patients with chronic arsenicosis.
Similar articles
-
Randomized placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic-contaminated water.J Toxicol Clin Toxicol. 2001;39(7):665-74. doi: 10.1081/clt-100108507. J Toxicol Clin Toxicol. 2001. PMID: 11778664 Clinical Trial.
-
Chronic arsenic toxicity in Bangladesh and West Bengal, India--a review and commentary.J Toxicol Clin Toxicol. 2001;39(7):683-700. doi: 10.1081/clt-100108509. J Toxicol Clin Toxicol. 2001. PMID: 11778666 Review.
-
Chronic arsenic toxicity: clinical features, epidemiology, and treatment: experience in West Bengal.J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003 Jan;38(1):141-63. doi: 10.1081/ese-120016886. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003. PMID: 12635824
-
Arsenic and non-malignant lung disease.J Environ Sci Health A Tox Hazard Subst Environ Eng. 2007 Oct;42(12):1859-67. doi: 10.1080/10934520701566926. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2007. PMID: 17952787
-
Strategies for safe and effective therapeutic measures for chronic arsenic and lead poisoning.J Occup Health. 2005 Jan;47(1):1-21. doi: 10.1539/joh.47.1. J Occup Health. 2005. PMID: 15703449 Review.
Cited by
-
Combined dimercaptosuccinic acid and zinc treatment in neurological Wilson's disease patients with penicillamine-induced allergy or early neurological deterioration.Biosci Rep. 2020 Aug 28;40(8):BSR20200654. doi: 10.1042/BSR20200654. Biosci Rep. 2020. PMID: 32809015 Free PMC article.
-
Arsenic intoxication: general aspects and chelating agents.Arch Toxicol. 2020 Jun;94(6):1879-1897. doi: 10.1007/s00204-020-02739-w. Epub 2020 May 9. Arch Toxicol. 2020. PMID: 32388818 Free PMC article. Review.
-
Treatment of lead and arsenic poisoning in anuric patients - a case report and narrative review of the literature.BMC Nephrol. 2019 Oct 17;20(1):374. doi: 10.1186/s12882-019-1561-1. BMC Nephrol. 2019. PMID: 31623560 Free PMC article. Review.
-
Biological effects and epidemiological consequences of arsenic exposure, and reagents that can ameliorate arsenic damage in vivo.Oncotarget. 2017 May 10;8(34):57605-57621. doi: 10.18632/oncotarget.17745. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915699 Free PMC article. Review.
-
Medicinal plants and natural products in amelioration of arsenic toxicity: a short review.Pharm Biol. 2017 Dec;55(1):349-354. doi: 10.1080/13880209.2016.1235207. Pharm Biol. 2017. PMID: 27931138 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical